Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Aquinox Pharmaceuticals, Inc..
Aquinox Pharmaceuticals, Inc. is a company.
Key people at Aquinox Pharmaceuticals, Inc..
Key people at Aquinox Pharmaceuticals, Inc..
Aquinox Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics targeting inflammation, inflammatory pain, and blood cancers by activating SH2-containing inositol-5'-phosphatase 1 (SHIP1).[1][4][5] Its lead product candidate, Rosiptor (Leadership 301), advanced to Phase III trials for interstitial cystitis/bladder pain syndrome, addressing unmet needs in chronic urological conditions through inflammation modulation.[4] Founded in 2006 as a spin-off from the University of British Columbia and BC Cancer Agency, the Vancouver-based company raised $65.84M before being acquired by Sun Pharma in July 2020, marking the end of its independent operations.[1][2]
Aquinox emerged in 2006 from academic research at the University of British Columbia and BC Cancer Agency, spinning off to commercialize SHIP1 activators discovered through university-led innovation.[1][2] The company incorporated its U.S. entity as Aquinox Pharmaceuticals (USA) Inc. around 2003-2006, rebranding to Aquinox Pharmaceuticals, Inc. in January 2014 to reflect its expanded scope.[4][5][6] Early traction built on a library of novel compounds, culminating in Rosiptor's Phase III progression and NASDAQ listing (AQXP), though it faced challenges leading to the 2020 acquisition by Sun Pharma.[1][4]
Aquinox rode the wave of precision immunology in biotech, targeting SHIP1 to balance immune responses amid rising demand for non-opioid pain therapies and inflammation treatments for aging populations.[1][4] Its timing aligned with post-2010 advances in phosphatase-targeted drugs, filling gaps in urological care where traditional anti-inflammatories fell short.[4] Market forces like increasing interstitial cystitis diagnoses and blood cancer prevalence favored its pipeline, while the 2020 Sun Pharma acquisition integrated its assets into a major player's global R&D ecosystem, influencing SHIP1 research trajectories.[1]
Post-acquisition, Aquinox's independent story closed, but its SHIP1 platform likely fuels Sun Pharma's inflammation pipeline, potentially accelerating Rosiptor or derivatives toward approval.[1] Evolving trends in targeted immunomodulators and non-addictive pain relief will shape its legacy, with patents extending influence into the late 2020s.[1] As biotech consolidates, Aquinox exemplifies how academic spin-offs drive innovation, their technologies enduring through acquirers to impact patient care in underserved inflammatory diseases—echoing its original mission of clinically meaningful therapeutics.[1][2][4]
